Daily Market Recap: October 8, 2025
Introduction
U.S. small-cap shares rallied broadly on October 8, with a cluster of biotech and tech-related issues posting double- and triple-digit gains. High trading volumes accompanied much of the upside, reflecting renewed investor appetite for early-stage companies ahead of key catalysts. Below is a summary of the day’s top movers, along with an analysis of overarching market trends.
Trading Summary Table
| Ticker | ATTN Price | Current Price | Volume | Price Change % |
|---|---|---|---|---|
| XBIO | 6.82 | 10.17 | 19,071,126 | 49.14% |
| GLTO | 8.64 | 10.20 | 1,121,439 | 18.00% |
| ACXP | 5.84 | 7.78 | 10,669,552 | 33.28% |
| RNAZ | 8.64 | 13.76 | 3,536,684 | 59.23% |
| YYAI | 0.101 | 0.2284 | 640,366,076 | 127.02% |
| PCSA | 0.390 | 0.4900 | 70,744,326 | 25.76% |
| UPC | 4.73 | 7.40 | 9,712,996 | 56.47% |
| NXL | 1.07 | 1.63 | 111,245,895 | 52.05% |
| COCH | 0.815 | 0.9370 | 7,975,473 | 14.94% |
| ZNB | 1.54 | 1.87 | 5,677,904 | 21.71% |
| TNMG | 0.312 | 0.4798 | 46,388,408 | 53.85% |
| AREB | 3.45 | 6.57 | 6,043,360 | 90.73% |
| SGLY | 0.469 | 0.6811 | 1,140,494 | 45.11% |
| EPWK | 0.048 | 0.0777 | 77,766,292 | 62.42% |
| NERV | 2.04 | 2.6995 | 4,848,956 | 32.12% |
| BIAF | 2.17 | 2.9500 | 18,251,954 | 36.19% |
| KYTX | 5.59 | 7.28 | 4,716,204 | 30.24% |
| ABVE | 2.63 | 4.5700 | 26,530,846 | 74.03% |
| CENN | 0.086 | 0.2536 | 42,692,728 | 195.81% |
| GTBP | 0.52 | 1.0400 | 41,042,323 | 98.55% |
Biotech Rally by Joseph Chan
Market Analysis
Thursday’s trading session saw significant upside across micro- and small-cap names, especially in the biotech and blockchain-focused sectors. CENN (Cenntro Inc.) led the advance, nearly tripling in price after management announced a strategic manufacturing pivot. Blockchain servicer AiRWA (YYAI) followed suit, more than doubling as tokenization trials gained traction. Both stocks traded with massive volumes, underscoring their newfound momentum.
Mid-caps with clinical or product milestones also attracted attention. GTBP surged on anticipation of early NK-cell therapy data, while ABOVE Food (ABVE) leapt after securing strategic partner support in a pending reverse merger. Despite broad gains, a few issues—such as COCH and ZNB—registered more modest improvements, reflecting selective investor focus.
Volume patterns revealed a bifurcation: breakout stocks drew tens to hundreds of millions of shares, while names with single-digit moves saw comparatively restrained turnover. This divergence suggests targeted capital flow toward event-driven catalysts rather than a general market re-risking.
Highlights of Notable Moves
- CENN nearly tripled on heavy volume after unveiling a shift to hydrogen fuel-cell R&D and a facility shake-up.
- YYAI jumped 127% as tokenization pilots on Solana progressed, drawing over 640 million shares in volume.
- GTBP rallied 98.6% amid NK-cell TriKE trial readout expectations, with volume topping 41 million.
- AREB climbed 90.7% following a 1-for-20 reverse split and S-1 filing, signaling fresh capital plans.
- EPWK surged 62.4% on robust interest in its energy-service platform, trading nearly 78 million shares.
TL;DR
- Small-cap biotech and blockchain names outperformed, led by CENN (+195.8%) and YYAI (+127.0%) on heavy turnover.
- Clinical-stage and reverse-merger candidates saw targeted inflows ahead of key catalysts.
- Volume concentration suggests event-driven trading dominates broader market re-risking.
